Purpose: To characterize errors in enhancement in breast dynamic contrast-enhanced (DCE) MRI studies as a function of echo time and determine the source of dark band artifacts in clinical subtraction images. Methods: Computer simulations, oil and water substitute (methylene chloride), as well as an American College of Radiology quality control phantom were tested. Routine clinical DCE breast MRI study was bracketed with (accelerated) inphase DCE acquisitions in five patients. Results: Simulation results demonstrated up to À160% suppression of the expected enhancement caused by differential enhancement of fat and water. Two-dimensional gradientrecalled echo and fat-suppressed 3D GRE phantom imaging confirmed the simulation results and showed that fat suppression does not eliminate the artifact. In vivo in-phase DCE images showed increased enhancement consistent with predictions and also confirmed increased spatial blurring on inphase 3D gradient-recalled echo images. Combined multidimensional partial Fourier and parallel imaging provided a time-equivalent in-phase DCE MRI acquisition. Conclusion: Errors in expected enhancement occur in DCE breast MRI subtraction images because of differential enhancement of fat and water and incomplete fat signal suppression. These errors can lead to artificial suppression of enhancement as well as dark band artifacts on subtraction images. These artifacts can be eliminated with a time-equivalent in-phase fatsuppressed 3D gradient-recalled echo sequence. Understanding chemical shift artifact of the third kind, a unique artifact of artificial enhancement suppression in the presence of intravoxel fat and water signal, will aid DCE breast MRI image interpretation. In-phase acquisitions (combined with simultaneous minimum echo time or opposed-phase echoes) may facilitate qualitative, quantitative and longitudinal analysis of contrast enhancement.
INTRODUCTION
Breast tissue contains a unique interdigitation of planes of fat and fibroglandular tissue ( Fig. 1) , leading to voxels with variable concentrations of fat. The American College of Radiology requires either chemical shift fatsuppressed dynamic contrast-enhanced (DCE) images or post-from pre-contrast subtraction images in the breast MRI protocol for accreditation (1) . Subtraction artifacts reduce the diagnostic use of these critical sequences. A common cause is patient motion (Fig. 2) . However, centers across the country have struggled for years with subtraction artifacts on breast MRI of unknown cause. Most are using short and wide bore scanners for patient comfort. These unexplained artifacts consist of hypointense bands consistently observed in the subtraction images ( Fig. 3 ) despite the lack of motion between the acquisitions (Supporting Fig. S1 ). The artifacts reduce reader confidence by introducing inhomogeneity and perceived misregistration as well as by confounding enhancement heterogeneity analysis. The artifacts persisted despite attempts over several years at protocol optimization by site physicists and vendor technicians (including using multiple types of fat suppression, e.g., chemical shift selective and spectral attenuated inversion recovery, modifying signal-to-noise ratio [SNR] , changing resolution, and switching from sagittal to axial plane imaging). These artifacts could not be explained by well-known chemical shift artifacts (2) of the first kind (fat signal shift in readout direction) or second kind (intravoxel phase cancellation at fat-water interfaces) (3), because they were present on the subtraction images only.
Contrast-enhanced breast MRI is carried out with a fatsuppressed 3D gradient-echo (GRE) technique with a minimum echo time (TE) and pulse repetition time (TR), which minimizes effective T the opposed-phase condition in abdominal imaging and termed "paradoxical suppression of fat" (6, 7) . There has been speculation on the potential for a fat-containing tumor or a small tumor surrounded by fat to be missed on subtraction of opposed-phase images as a result of this artifact (7, 8) .
The purpose of this study was to characterize errors in contrast enhancement at all off-resonance phase angles between fat and fibroglandular tissue (angle between fat and water magnetization vectors and to fully characterize the phenomenon previously reported in the opposedphase condition) and to determine whether the subtraction artifacts could be removed by imaging with an inphase time-equivalent sequence. This was preliminarily presented at the International Society for Magnetic Resonance in Medicine (9) .
METHODS

Computer Simulations
Simulations of voxels containing 0-100% mixtures (1% increments) of fat and water were carried out using MATLAB (MathWorks, Natick, MA). The lipid magnetization vector was simulated with an off-resonance phase angle of -180
to 180 compared to water magnetization vector in 1.8 steps. Fifty percent enhancement was assumed for the water (i.e., fibroglandular) component and 10% enhancement for fat (values obtained from patient DCE MRI measurements and correspond with previously reported values) (6) . Complex addition of fat and water components was carried out (M ¼ M w þ M f ; a vector addition of the two components as happens physically) before and after contrast enhancement followed by subtraction of magnitude values [jM post j -jM pre j] (carried out automatically on the scanner for subtraction images). Magnetization relaxation was ignored.
Phantom Experiments
Water and fat are not miscible. Therefore, methylene chloride CH 2 Cl 2 (Carolina Biological Supply Company, Burlington, NC) was chosen to simulate water because of its similar proton chemical shift (d CH2Cl2 ¼ 5.3 ppm vs. 4.7 for water) (10) and miscibility with oil (11) . As a result of the different chemical shift from water, fat and methylene chloride are opposed-phase at 1.96 ms and in-phase at 3.91 ms at 1.5T. Similar to prior work, chromium acetylecetonate (CrAcAc) (Sigma-Aldrich, Milwaukee, WI) served as the doping agent. Safflower oil (LouAna, Brea, CA) was used to simulate adipose fat (12) . Four stock solutions were created. Solution 1 was pure safflower oil, simulating breast adipose tissue (T 1 /T 2 $330/53 ms) (13) . Solution 2 contained methylene chloride þ 1 mM CrAcAc, simulating unenhanced fibroglandular breast tissue (T 1 /T 2 $1200/58 ms) (13) . Solution 3 contained safflower oil þ 1.4 mM CrAcAc to simulate enhanced adipose tissue. Solution 4 contained methylene chloride þ 2.1 mM CrAcAc to simulate contrast-enhanced glandular tissue. One set of glass vials was filled with 10 mL total volume in each vial: 0-10 mL from solution 1 in 1 mL increments, and 10-0 mL in À1 mL increments of solution 2 to simulate 0-100% lipid fractions (in 10% increments, 11 vials) before enhancement. A second set of vials was prepared similarly with 10 mL total volume using solutions 3 and 4 to simulate 0-100% lipid fractions (in 10% increments) of glandular breast tissue and adipose fat after contrast enhancement. The relaxivity of CrAcAc was calculated to be 0.64/(mMs) based on data from Hilaire et al. (11) . The concentration of CrAcAc was determined using the desired T 1 of fat and fibroglandular tissue provided above and the unenhanced T 1 of safflower oil and methylene chloride measured experimentally. The T 1 /T 2 values of the solutions were determined to be: CH 2 3 (89/47 ms), and solution 4 (646/527 ms). No attempt was made to shorten T 2 of the phantoms mimicking fibroglandular tissue because the longest TE (6 ms) was short compared to T 2 (58 ms), and the theoretical maximal signal reduction was 1 À exp(À6/58) ¼ 10% (5) . Assuming relatively small change in T 2 before and after contrast, the effect of T 2 relaxation cancels in the % change calculations, and finally, the spoiled GRE signal is modulated by T Ã 2 that is scanner-and patient-dependent, making achieving a specific value for T 2 less useful.
The vials in a plastic holder were submerged in a water bath to minimize susceptibility effects and placed in a single-channel head coil in a 1.5T scanner (Siemens Avanto, Erlangen, Germany). Care was taken to align similar lipid-concentration vials in the receive coil along its longitudinal axis of symmetry and the pre-scan normalize filter was used to minimize receive coil inhomogeneity on the subtraction. The T 1 of the solutions were measured using a fit to an exponential in MATLAB to spin-echo experiments. TR was varied from 20 ms-10 s with TE ¼ 12.6 ms. T 2 was calculated using a fit to exponential decay using multi-echo spin-echo sequence (TE ¼ 50-1600 ms in 32 steps), TR ¼ 10,000 ms. An initial experiment was carried out using a single-slice 2D GRE sequence, varying TE ¼ 2.0-6.0 ms in steps of 0.2 ms, with slice thickness ¼ 10 mm, TR ¼ 8.1 ms, 32 averages, matrix ¼ 256 Â 256, receiver bandwidth (BW) ¼ 675 Hz/ pixel (px), flip angle (FA) ¼ 10
, and field-of-view (FOV) ¼ 300 Â 300 mm. A second experiment was carried out using a fat-suppressed 3D VIBE sequence similar to those used clinically but modified for use with the singlechannel coil (generalized autocalibrating partially parallel acquisition parallel imaging factor of 2 removed and slices reduced from 196 to 120, assume dominant fat flag turned off). Acquisition parameters included TE ¼ 1.5-5.9 ms in steps of 0.2 ms, TR ¼ 4.5 ms (TE ¼ 1.5-2.7 ms) and then increased every TE thereafter using the minimize TR flag (longest TR ¼ 7.67 ms for TE ¼ 5.9 ms), number of phase encoding lines ¼ 538, BW ¼ 450 Hz/px, FA ¼ 10 , image matrix ¼ 384 Â 384, FOV ¼ 320 Â 320 mm, and slice thickness ¼ 1 mm. The default clinical sequence has spectral attenuated inversion recovery fat suppression (14) and 6/ 8 partial Fourier (PF) in the partition-encode direction. The data were analyzed using OsiriX Lite (Bernex, Switzerland). A circular region-of-interest was drawn and the mean (magnitude) signal recorded for each vial. Subtraction and % error calculations were carried out on the magnitude data as is done clinically on subtraction DCE images.
To maintain the temporal resolution of the DCE study, the in-phase acquisition was accelerated to compensate for the longer TR. A time-equivalent acquisition was designed with increased PF in both partition and phaseencode dimensions. Prior studies have successfully combined PF in two dimensions (15) as well as PF and parallel imaging (16) . Therefore, it was felt that this acceleration method could be used to reduce acquisition time while not affecting image contrast. Furthermore, SNR calculations revealed the SNR gained by imaging at a longer TR required at the in-phase echo-time matched the SNR lost by increased PF imaging. Therefore, there was no SNR penalty.
Additional phantom experiments were carried out to investigate high-contrast spatial resolution and low-contrast object detectability using the standard minTE/TR clinical VIBE sequence as well as modified versions leading to the time-equivalent in-phase version.
The large American College of Radiology quality control phantom was used containing standard inserts for these measurements (17). High-contrast spatial resolution was measured by determining the smallest set of holes that could be independently resolved in horizontal and vertical dimensions. For low-contrast detectability, the number of rungs on which all three discs could be seen were counted. Four versions of the sequence were tested including (1) standard clinical spectral attenuated inversion recovery fat-suppressed VIBE sequence (TE/TR ¼ 1. 
Human Imaging
Clinical DCE MRIs are carried out on a short and widebore 1.5T scanner (Siemens Espree, Erlangen, Germany). This is done to use the same system for MR-guided needle biopsy when needed and for patient comfort. Images were obtained in the sagittal plane for planning of an image-guided biopsy using a fat-suppressed VIBE sequence. Acquisition parameters included: slice thickness ¼ 2. FIG. 4. Paradoxical contrast enhancement. Schematic depicting water, fat, and total voxel signal in the opposed-phase condition for a voxel containing 75% fat and 25% water before and after contrast administration as well as the subtraction of voxel magnitudes. A 50% enhancement of fibroglandular tissue and 10% enhancement of fat signal have been depicted. Before contrast, there is partial phase cancellation of fat and water signals (chemical shift artifact of second kind, intravoxel phase cancellation). After contrast administration, there is a larger increase in water signal than fat because of its greater perfusion resulting in increased phase cancellation of the fat and water signals. The overall voxel signal is reduced and the subtraction is negative (star).
Images were analyzed in MATLAB by drawing horizontal and vertical profiles through the images to measure translation.
In vivo testing was carried out to assess the ability to improve the image quality of the clinical DCE protocol. The project was reviewed and determined to qualify as Quality Improvement by the University of Pennsylvania's Institutional Review Board. Testing was done on five patients undergoing routine clinical breast DCE MRI studies. On all patients, verbal informed consent was obtained before the study. To not alter the standard DCE clinical images, the routine breast MRI protocol was carried out, with the addition of in-phase fat-suppressed 3D GRE acquisitions bracketing (before and after) the standard minTE DCE study (the standard DCE study includes one fat-suppressed 3D GRE acquisition before and three acquisitions after intravenous administration of gadolinium contrast agent). For three patients, the only change in the modified bracketing DCE acquisition was changing the TE from the minTE to the in-phase echo-time (with a corresponding increase in TR), resulting in a TE ¼ 4.8 ms and scan time increase of $1.5 min for each 3D acquisition (only one in-phase post contrast acquisition was carried out to limit additional scan time to $8 min total for patient comfort). For two patients, the time-equivalent in-phase acquisition was used, having increased PF from 6/8 to 5/8 in partition and from 8/8 (off) to 6/8 in phaseencoding dimensions. In the accelerated in-phase bracketed studies, multiple in-phase post-contrast data sets were acquired while limiting total scan time increase to $10 min. The standard clinical DCE MRI acquisition time for each volumetric study was $2.5 min, for the inphase scan was $4 min and for the time-equivalent inphase acquisition was several seconds shorter than the routine minTE study. As a result of bracketing the clinical study, there was an increased delay between the preand post-contrast in-phase images as well as an increased delay between contrast injection and in-phase post-contrast images. The modified in-phase sequence used the in-phase echo-time flag available on the scanner, which used TE ¼ 4.8 ms at 1.5T (slightly longer than the predicted in-phase echo time of fat and water at 1.5T of 4.6 ms, because of B 0 slightly lower than 1.5T). Manual subtraction of magnitude images as well as magnitude profile analysis was carried out in MATLAB. Figure 5 shows the simulation results. Figure 5a shows the simulated total voxel magnitude as a function fat fraction (0-100% fat, and hence 100-0% water). Note phase cancellation for a 50-50 fat-water voxel in the opposed-phase condition. Figure 5b shows a similar plot after contrast enhancement. The water voxel enhances by 50% and the pure fat voxel by 10%. The phase cancellation now occurs at a higher proportion of fat, because the fat component enhances less than water. Figure 5c shows the subtraction (jM enhanced j -jM unenhanced j). Enhancement (subtraction) is a linear function of water content while in-phase, but has non-linearity when out of phase. There is negative enhancement (below dotted line) when fat and water are near the opposed-phase condition (i.e., paradoxical enhancement for 160 and 180 curves). Figure 5d plots the normalized % error in enhancement from in-phase [100*(sub(f) -sub(f ¼ 0))/ sub(f ¼ 0)]. Changes in enhancement are negative and increase when the fat-water phase angle increases. Enhancement suppression is up to À160% of the expected enhancement. Error increases when there is more fat than water signal. Figure 5e shows the normalized subtraction error (from in-phase condition), re-plotted as a function of fat-water phase angle. When imaged in-phase, there is no error in enhancement, regardless of fat signal; error increases as fat-water phase angle increases. Figure 5f is a contour plot of subtraction error as a function of both fat signal fraction and fat-water phase angle. There is < 20% error within 6 60 fat-water phase angle for all fat signal fractions. The largest errors occur at the opposed-phase condition (6180 ) with 60% fat signal fraction. Figure 6 plots the 2D gradient-echo phantom results (without fat suppression). In Figure 6a , fat has four to five times higher signal magnitude than water due its shorter T 1 . Signal cancellation occurs at a lower oil fraction ($30%) because of the higher lipid signal. Phase cancellation increases as the echo-time approaches the out-of-phase condition (TE ¼ 2.0 ms). Figure 6b shows the signal magnitude from vials doped with additional CrAcAc simulating enhanced tissue (note both methylene chloride and fat vials have increased in intensity, as expected). Figure 6c plots the subtraction of vials (jM enhanced j -jM unenhanced j), which shows near-uniform enhancement of the vials regardless of oil content when imaging near the in-phase condition (TE ¼ 3.8 and 4.0 ms). As predicted in simulations, there is enhancement suppression as TE is shortened to the opposed-phase condition (TE ¼ 2.0 ms), with paradoxical enhancement observed at three echo times (TE ¼ 2.0, 2.2, and 2.4 ms), the TEs closest to the opposed-phase condition. Figure  6d shows the % error in subtraction from the in-phase condition. There is enhancement suppression that is a function of echo-time (fat-water phase angle); the maximal reduction occurs at TE ¼ 2.0 ms (opposed-phase condition) with 159% enhancement suppression. Figure 6e plots subtraction error from in-phase as a function of echo time. There is no error in enhancement at the inphase condition (dotted line, TE ¼ 3.9 ms) regardless of fat signal, with exponential error increase as phase angle increases to the opposed-phase condition (TE ¼ 2.0 or 5.9 ms, first and second opposed-phase conditions, respectively). Figure 6f shows a contour plot of % error from in-phase. The maximal errors occur at TE ¼ 2.0 and 6.0 ms (opposed-phase conditions) and 40% oil fraction. Substantial reductions in observed enhancement occur over a large range of echo times (TE ¼ 2.0-3.3 ms and 4.5-6 ms) and over a large range of fat signal content, including oil fractions as low as 15%. Low (<10%) errors in enhancement occur from TE ¼ 3.5-4.5 ms, centered on the in-phase condition (TE ¼ 3.9 ms) for all fat signal fractions. Figure 7 depicts the fat-suppressed 3D GRE phantom results. Figure 7a shows the signal magnitude from vials simulating unenhanced tissue. The signal from the 100% lipid vial has been reduced because of the applied fat suppression, to below the level of pure methylene chloride vial (e.g., at TE ¼ 2.5 ms, signal magnitude is 110 vs. 150 for methylene chloride). Compared to the fat unsuppressed experiment, there is $85% relative fat signal attenuation because of the spectral attenuated inversion recovery fat suppression. However, the suppressed lipid signal is now $75% of the methylene chloride signal at this TE. There is increased lipid signal as TE increases as a result of obligatory TR increase, demonstrating rapid lipid signal regrowth (e.g., 145% fat signal increase at TE ¼ 3.9 ms). Voxel signal cancellation occurs at a higher lipid fraction (90%), because the lipid signal has been suppressed. Figure 7b plots the magnitude of the vials simulating enhanced tissue; both methylene chloride and lipid signals have increased, as expected. Figure 7c shows the subtraction (jM enhanced j À jM unenhanced j), again demonstrating reduction in subtraction signal from in-phase condition as a function of TE, with paradoxical enhancement for TE values of 1.9-2.5 ms near the opposed-phase condition (TE ¼ 2.0 ms). Figure 7d plots % subtraction error from the in-phase condition; the suppression again increases as TE is shortened and is greater in voxels with more lipid than methylene chloride. The maximal reduction in enhancement is 141%. Figure 7e plots subtraction error as a function of echo-time. Again, no error is observed regardless of oil fraction near the in-phase condition (TE ¼ 3.9 ms, dotted line). Error exponentially increases as TE is shortened or lengthened, thereby increasing the methylene chloride-lipid phase angle. The maximal error or reduction occurs at TE ¼ 2.3 ms, near the opposed-phase condition. Figure 7f shows the contour plot of the normalized error as a function of echo-time and fat signal fraction. There are negligible errors in enhancement near the in-phase condition (TE ¼ 3.9 ms, dotted line) and substantial errors (>20%) from TE ¼ 1.6-3.5 ms and 4.8-6 ms). An oil fraction of 40% is required to create >10% errors in enhancement because of the use of fat-suppression. Figure 8 depicts DCE MRI images obtained using the standard clinical minTE/TR and the modified in-phase acquisitions. The minTE/TR images demonstrate high spatial resolution in the nonsubtraction images (Figs. 8a,  b) . However, there are many areas with little or no enhancement throughout the breast on the subtraction image ( Fig. 8c) with areas of signal below the fat enhancement level. These give an impression of dark serpiginous band artifacts throughout the breast, which are better appreciated when scrolling through the 3D volume. There was no motion between pre and post-contrast images as shown in Supporting Figure S1 (available online). On the in-phase images, there is resolution degradation (spatial blurring) in nonsubtraction images (Figs.  8d, e) . There are also subtle linear hypointense structures radiating from nipple to chest wall (arrow in Fig. 8d ). In the in-phase subtraction image (Fig. 8f) , there are multiple areas of increased enhancement (arrows), most notably in the skin and peripheral right breast as well as both peripherally and centrally in the left breast. Of note, there is a horseshoe-shaped enhancing lesion in the posterolateral left breast that appears more uniform on the in-phase images compared to minTE image (Fig. 8c) . Figure 9 shows quantitative differences between the minTE and in-phase subtraction images (Figs. 8c, f) . Figure  9a plots the % difference from minTE to in-phase subtraction images (i.e., 100*[sub(in-phase) -sub(minTE)]/ sub(minTE)). Note the widespread areas of low-spatialfrequency increase in enhancement in the 100-200% range. Note that the increases are non-uniform throughout each breast and different between the breasts, indicating the difference is not simply because of the slightly longer delay from injection to in-phase image acquisition. There are narrower (high spatial frequency) areas of signal increase/decrease, which may represent edge effects as a result of the differences in image resolution from the blurring observed in the in-phase acquisition. Comparison profiles drawn through the subtraction images (Figs. 9b-d) show multiple areas of substantial increased signal in the in-phase subtraction compared to minTE subtraction images. The increases are non-uniform throughout each breast and different between the breasts, representing true increases in enhancement signal in both breasts in the in-phase acquisition. These are not high spatial frequency, but rather match the spatial extent of enhancement in the minTE subtraction profile. Therefore, the increased intensity do not represent edge effects but rather true geographic areas of increased breast DCE signal. Figure 10 depicts horizontal and vertical profiles through the right breast at another slice location in the mid breast (same patient as Figs. 8 and 9 ). These profiles show there was no translation of the breast in the imaging plane (circles denote edges of breast) on the nonsubtraction images. Despite the lack of motion, there are multiple areas of subtraction signal below zero in the minTE subtraction (dotted lines, arrows) that are not present on the in-phase subtraction. These correspond to the dark band artifacts observed in the clinical minTE subtraction images, caused by paradoxical contrast enhancement, which have been removed with in-phase imaging.
RESULTS
Images from a time-equivalent in-phase DCE study is provided online (Supporting Fig. S2 ). The resulting images are similar to the less accelerated in-phase data. Specifically, the minTE data have high spatial resolution, however, there is less enhancement and more serpiginous dark band artifacts in the subtraction image. Inphase images have decreased spatial resolution as well as subtle linear dark signal representing Cooper's ligaments in the breast. The in-phase subtraction image shows greater enhancement in the skin and breast, and the central serpiginous dark bands have been removed. The field-of-view was changed while optimizing the clinical DCE study at the scanner causing a small mismatch between pre-and post-contrast in-phase images, corrupting subtraction data from the first two in-phase subtractions, therefore, data from the third post-contrast in-phase DCE study is shown.
Supporting Table S1 (available online) sequence with imaging time of 2 min 17 s had a spatial resolution of 1.1 mm and a score of 26 on the lowcontrast detectability test. Both the in-phase as well as the time-equivalent in-phase VIBE sequences had a high contrast spatial resolution of 1.0 mm and low contrast detectability score of 31. Therefore, the modified inphase sequence performed better on these objective tests, indicating that the loss of spatial resolution observed in vivo was not related to loss of spatial resolution in the sequence itself (e.g., from acceleration using multidimensional PF combined with parallel imaging and/or reconstruction algorithm errors).
DISCUSSION
Unexplained hypointense band artifacts present on breast DCE MRI subtraction images without motion are caused by increased phase cancellation between fat and fibroglandular tissues after contrast administration when not imaged in-phase and also result in artificial suppression of enhancement in subtraction images. This phenomenon was previously described on nonsubtraction images in the abdomen on opposed-phase imaging only. In this paper, this artifact was studied at all out-of-phase conditions and specifically with respect to the effect on subtraction images, with emphasis on breast DCE MRI. Simulation results and phantom experiments confirm enhancement suppression by up to À160%. Therefore, the expected enhancement can be altered anywhere from the expected physiological or full enhancement to null (complete masking of enhancement) and even negative (paradoxical enhancement). The simulation and phantom results have characterized this phenomenon, termed chemical shift artifact of the third kind (as it does not always lead to paradoxical enhancement), over all fat-water phase angles (echo times) and all fat signal concentrations. A time-equivalent in-phase sequence was tested in vivo, which eliminated this artifact.
Breast MRI is used to screen high risk women for breast cancer (18, 19) , as a problem solving tool for complex cases screened using mammography and ultrasound, to stage local disease, to assess response to chemotherapy, and to differentiate postsurgical changes from cancer recurrence (19, 20) . Studies are assessed and reported using the Breast Imaging and Reporting Data System. The intensity of contrast enhancement, the enhancement dynamics (persistent, plateau and washout), as well as homogeneity of enhancement are assessed (20) .
The amount and pattern of enhancement have diagnostic and prognostic significance. Tumor enhancement is a result of angiogenesis as well as tumor grade (21, 22) and correlates with lymph node status at surgery and tumor grade at pathology (23) . DCE metrics (area under the enhancement curve, enhancement index at 30 s) have a higher hazard ratio for determining disease-free survival and overall survival than both tumor size and pathological grade (24) . Higher enhancement ratio (both % increase and post-/pre-ratio) predicts favorable response to chemotherapy (25) . Changes in enhancement can be used to monitor effectiveness of neoadjuvant chemotherapy and predict residual disease (25, 26) . Enhancement is a surrogate marker for aggressive disease phenotypes (higher tumor grade, estrogen receptor/progesterone receptor negative, and high Ki-67 score) (27) (28) (29) . Contrast washout correlates with metabolic activity at 18 F-fluorodeoxy glucose-positron emission tomography (30) , and enhancement of background tissue around a tumor correlates with ipsilateral breast cancer recurrence risk (31,32).
Enhancement heterogeneity is a marker of malignancy (33) (34) (35) . Peak enhancement may correlate with grade of pre-malignant entities such as ductal carcinoma in situ (36) . Lesion enhancement is critical for conspicuity and correlates inversely with interpretation time and missed cases (37) . More complex spatio-temporal analyses of the pharmacokinetics of contrast uptake during DCE MRI using wavelets has shown that quantitation of intratumoral heterogeneity of the dynamics allows improved prediction of breast cancer recurrence risk (38) . Data from multi-site trials have shown that functional tumor volumes measured using enhancement thresholds from DCE data predict recurrence-free survival (39) .
Therefore, equally if not more important than the desire to understand and eliminate the subtraction dark band artifacts, is the need to avoid artificially suppressing enhancement to accurately detect, judge, and quantitate contrast enhancement. There are limitations with the current method of minimizing TE/TR to minimize scan time and T Ã 2 effects. For example, the effectiveness and/or method of fat signal suppression may change from scan to scan based on magnetic field homogeneity and shimming, which will lead to variable amount of enhancement suppression. Also, scan parameter choice such as field-ofview, resolution, phase oversampling, scan plane selection, etc. will all affect the minimum achievable TE and therefore the degree of enhancement suppression. Finally, several hardware constraints such as field strength (B 0 ) as well as gradient strength and slew rate will affect the inphase condition and minTE, respectively. Therefore, these changes will lead to variable levels of enhancement suppression from scan to scan that will impact the perceived enhancement, potentially leading to difficulty or erroneous judgments about the presence of disease or response to treatment. Carrying out DCE MRI in-phase using the time-equivalent sequence proposed here would eliminate much of this variability, which is important not only for longitudinal analysis of the patient but also for multi-site clinical trials to avoid a potentially confounding variable.
Linear hypointense bands radiating from the nipple to chest wall on in-phase nonsubtraction images are felt to represent Cooper's ligaments or collagen suspensory ligaments of the breast (40) . As a result of the short T Ã 2 , they appear hypointense at the longer TE. The in-phase nonsubtraction images demonstrate spatial resolution degradation (spatial blurring). Other authors (41) documented moderate spatial blurring in 3D GRE abdominal imaging, which was worse in-phase compared to opposed-phase. The authors noted that this artifact is not well documented in the literature. This study corroborates the finding of increased spatial blurring in in-phase imaging. We believe the effect is accentuated here because of the larger difference in echo time between minTE to in-phase imaging (e.g., 4.8-1.6 ms ¼ 3.2 ms) compared to opposed-phase to in-phase imaging (4.8-2.4 ms ¼ 2.4 ms). This likely implies that the blurring is T Ã 2 -dependent and is likely worse in the breast than abdomen because of closer proximity to air-tissue interfaces. American College of Radiology quality control phantom experiments showed the modified in-phase sequence had improved high-contrast spatial resolution and low-contrast detectability. Therefore, the spatial blurring is caused by T Ã 2 blurring of breast in vivo in the clinical Espree (short and wide bore) scanner at the longer TE, as opposed to a problem with the image acquisition or reconstruction (as was confirmed on in-phase non-accelerated imaging). At 3T, the in-phase condition occurs at a shorter TE (2.3 ms) and may reduce the T Ã 2 blurring effect, as might scanning in a magnet with higher magnetic field homogeneity and/or with improved shimming. As was shown in (41) there is significantly less blurring using 2D instead of 3D GRE images, which could be used. It is important to note that while the nonsubtraction images are referenced during image interpretation, the subtraction images are the key images as a result of the subtlety of the changes on the nonsubtraction images. Therefore, having improved contrast enhancement on the subtraction may outweigh some loss of resolution on nonsubtraction images. Furthermore, high-resolution volumetric T 2 -weighted images (1.0 Â 1.0 Â 3.0 mm STIR) are acquired during the standard clinical DCE exam, mitigating loss of Figures 8 and 9 . Note the good alignment of the breast edges (circled for comparison) before (pre-) and after (post-) contrast administration, indicating there has been no bulk translation of the breast during either acquisition period. The unsigned integer (csub U) as well as real (csub R) subtraction profiles are plotted with a À300 offset for clarity. Note the areas of real subtraction signal below the offset (dotted lines, arrows) denoting paradoxical enhancement present on the minTE subtractions, which are not present on the in-phase subtractions.
spatial resolution on the nonsubtraction T 1 -weighted images. Some spatial blurring in the nonsubtraction DCE images also protects against motion-induced dark band artifacts in the subtraction images, which are frequently observed clinically and have proven challenging to eliminate.
The in-phase acquisition acquired a single echo centered at the in-phase echo time (TE ¼ 4.8 ms at 1.5T). Without any increase in scan time, a second earlier echo could be obtained at the minTE to provide the high resolution T 1 -weighted images to use in conjunction with the in-phase subtraction, thereby eliminating the spatial resolution degradation on in-phase non-subtraction images. Alternatively, a second echo could be centered on the opposed-phase echo time (TE ¼ 2.4 ms) to obtain two-point Dixon data, which would also allow fat and water signal to be separated. This study may provide further rationale for carrying out Dixon/IDEAL fat-water decomposition in the breast.
Gradient-echo T 1 -weighted pre-and post-contrast imaging is carried out routinely in all subspecialties of clinical radiology. It is important to understand the chemical shift artifact of the third kind, as there are significant clinical implications for contrast-enhanced imaging of any structure or tumor that is composed of or juxtaposed with fat and non-fatty tissues (whose presence is often unknown before imaging).
CONCLUSION
Currently, clinical contrast-enhanced imaging is carried out with minTE/TR to minimize scan time and T Ã 2 effects. However, this can create significant limitations regarding suppression of contrast enhancement (up to À160%) in voxels containing a mixture of fat and water signal. Here, we document resulting dark band artifacts in clinical subtraction breast DCE MRI, which interfere with interpretation of images and show the elimination with a time-equivalent in-phase sequence. To eliminate both the subtraction artifact as well as errors and variability in contrast enhancement, consideration should be given to carrying out gradient-echo contrast-enhanced imaging in-phase.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article. Fig. S1 . Horizontal as well as vertical profiles through the (a) right and (b) left breasts obtained from the images in Figure 3 . The edges of the breast are circled; note the good alignment of the breast edges confirming lack of bulk translation between the DCE image acquisitions. The legend for the profiles is provided in Figure 2d . The subtraction profiles are plotted with a negative offset for clarity. Fig. S4 . Low-contrast detectability testing of clinical VIBE sequence (minTE/TR 5 1.5 ms/4.5 ms), slice PF 5 6/8, T acq 5 2:17 (min:s). Disks having (a) 5.1%, (b) 3.6%, (c) 2.5%, and (d) 1.4% contrast. The number of contiguous spokes seen at each contrast level is indicated in the bottom right of each image. This sequence had a total low-contrast detectability score of 26. Fig. S5 . Low-contrast detectability testing of in-phase VIBE sequence (TE/ TR 5 4.8 ms/7 ms), slice PF 5 6/8, T acq 5 3:19 (min:s). Disks having (a) 5.1%, (b) 3.6%, (c) 2.5%, and (d) 1.4% contrast. The number of contiguous spokes seen at each contrast level is indicated in the bottom right of each image. This sequence had a total low-contrast detectability score of 31. Fig. S6 . Low-contrast detectability testing of slice-accelerated in-phase VIBE sequence (TE/TR 5 4.8 ms/7 ms), slice PF 5/8, T acq 2:59 (min:s). Disks having (a) 5.1%, (b) 3.6%, (c) 2.5%, and (d) 1.4% contrast. The number of contiguous spokes seen at each contrast level is indicated in the bottom right of each image. This sequence had a total low-contrast detectability score of 30. Fig. S7 . Low-contrast detectability testing of slice and phase-encode accelerated in-phase VIBE sequence (TE/TR 5 4.8 ms/7 ms), slice PF 5 5/8, phase PF 5 6/8, T acq 5 2:16 (min:s). Disks having (a) 5.1%, (b) 3.6%, (c) 2.5%, and (d) 1.4% contrast. The number of contiguous spokes seen at each contrast level is indicated in the bottom right of each image. This sequence had a total low-contrast detectability score of 31. Table S1 . ACR Quality Control Phantom Experiment Summary
